

GLAXOSMITHKLINE PLC  
Form 6-K  
October 01, 2009

**FORM 6-K**

**SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549**

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

For period ending October 2009

**GlaxoSmithKline plc**  
(Name of registrant)

**980 Great West Road, Brentford, Middlesex, TW8 9GS**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

--

### Total Voting Rights and Capital

In  
conformity with  
Disclosure and  
Transparency  
Rule 5.6.1R

,  
GlaxoSmithKline plc ("the Company")  
hereby notifies the market of the following:

The Company's issued share capital as at  
30 September

2009 consisted of  
5,662,  
902,704  
Ordinary shares of 25p each with voting rights, of  
which  
474,194,158  
Ordinary shares are held in Treasury.

Therefore, the  
total number of voting rights in the Company is

5,188,708,546

. This figure may be used by shareholders as the denominator for the calculations by which  
they will determine if they are required  
to notify their interest in, or a change to their interest in,  
the Company  
under the  
Financial Services Authority's  
Disclosure and Transparency Rules

S M Bicknell  
Company Secretary

1 October

2009

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

**GlaxoSmithKline plc**  
(Registrant)

Date: October 1 2009

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc